← All drugs
Drug · FAERS side-effect profile with label screen

Acetaminophen side effects: what 444,741 FDA adverse event reports show

Acetaminophen · 1,171 reaction terms · 2,312,474 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

444,741 reports · 72% serious · 62,469 with death outcome · 65% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Acetaminophen injection is indicated for • the management of mild to moderate pain in adult and pediatric patients 2 years and older • the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older • the reduction of fever in adult and pediatric patients.

FDA label, Indications and Usage

What it is

Paracetamol is a member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

PubChem CID 1983 (ChEBI)

Boxed warning

RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 7Reporting / coding artifact 1Lab value / disease marker 11Not in label — unassessed 21
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,131 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Blood pressure diastolic abnormal1,876129.1
118.2–141.1ROR 129.7 · calibrated p 2e-8 ✓
34.4 EB05 33.1 · IC025 +5.0
3/3 methods agree
Lab value / disease markerserious n=1,781 · 90% clinicianno trial arm names this drug
Blood pressure systolic abnormal1,720106.0
97.3–115.6ROR 106.4 · calibrated p 7e-8 ✓
32.5 EB05 31.3 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious n=1,635 · 90% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody454100.8
85.4–118.8ROR 100.9 · calibrated p 1e-7 ✓
32.0 EB05 29.6 · IC025 +4.8
3/3 methods agree
Lab value / disease markerserious n=454 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Lupus vulgaris79294.1
83.3–106.3ROR 94.2 · calibrated p 2e-7 ✓
31.3 EB05 29.5 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=792 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive4,60687.0
82.8–91.4ROR 87.9 · calibrated p 3e-7 ✓
30.5 EB05 29.8 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious PRR 24.4 · ♀ 100% (drug 65%) · 94% clinicianno trial arm names this drug
Rheumatic fever2,80784.8
79.7–90.3ROR 85.4 · calibrated p 4e-7 ✓
30.3 EB05 29.3 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=2,806 · ♀ 100% (drug 65%) · 94% clinicianno trial arm names this drug
Swollen joint count increased1,97681.5
75.7–87.7ROR 81.9 · calibrated p 5e-7 ✓
29.8 EB05 28.7 · IC025 +4.8
3/3 methods agree
Lab value / disease markerserious n=1,973 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Deep vein thrombosis postoperative1,24281.4
74.2–89.3ROR 81.6 · calibrated p 5e-7 ✓
29.8 EB05 28.4 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=1,242 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
C-reactive protein56878.8
68.8–90.2ROR 78.9 · calibrated p 7e-7 ✓
29.4 EB05 27.5 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=568 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Duodenal ulcer perforation4,56477.4
73.8–81.2ROR 78.2 · calibrated p 7e-7 ✓
29.3 EB05 28.6 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious PRR 23.3 · ♀ 100% (drug 65%) · 94% clinicianno trial arm names this drug
Facet joint syndrome1,72556.6
52.7–60.7ROR 56.8 · calibrated p 6e-6 ✓
25.8 EB05 24.8 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=1,721 · ♀ 100% (drug 65%) · 94% clinicianno trial arm names this drug
Exposure to toxic agent1,70652.7
49.1–56.5ROR 52.9 · calibrated p 1e-5 ✓
24.9 EB05 24.0 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=1,697 · 100% clinicianno trial arm names this drug
Rheumatoid factor positive2,92047.9
45.5–50.4ROR 48.2 · calibrated p 2e-5 ✓
23.8 EB05 23.1 · IC025 +4.5
3/3 methods agree
Lab value / disease markerserious n=2,919 · ♀ 100% (drug 65%) · 95% clinicianno trial arm names this drug
Adjustment disorder with depressed mood97844.0
40.3–48.0ROR 44.1 · calibrated p 3e-5 ✓
22.8 EB05 21.7 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=973 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Helicobacter infection4,70740.0
38.5–41.6ROR 40.4 · calibrated p 5e-5 ✓
21.7 EB05 21.2 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious PRR 18.2 · ♀ 100% (drug 65%) · 93% clinicianno trial arm names this drug
X-ray abnormal80137.9
34.5–41.6ROR 38.0 · calibrated p 7e-5 ✓
21.1 EB05 19.9 · IC025 +4.3
3/3 methods agree
Lab value / disease markerserious n=801 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Folliculitis4,52436.3
34.9–37.7ROR 36.7 · calibrated p 9e-5 ✓
20.6 EB05 20.1 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious PRR 19.2 · ♀ 100% (drug 65%) · 93% clinicianno trial arm names this drug
Dislocation of vertebra97336.2
33.3–39.4ROR 36.3 · calibrated p 9e-5 ✓
20.6 EB05 19.5 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=973 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Pemphigus5,22933.8
32.6–35.0ROR 34.2 · calibrated p 1e-4 ✓
19.8 EB05 19.4 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious PRR 15.8 · ♀ 100% (drug 65%) · 93% clinicianno trial arm names this drug
Hand deformity5,41732.9
31.8–34.0ROR 33.3 · calibrated p 1e-4 ✓
19.5 EB05 19.1 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious PRR 16.8 · ♀ 100% (drug 65%) · 91% clinicianno trial arm names this drug
Analgesic drug level increased60427.7
25.0–30.6ROR 27.7 · calibrated p 4e-4 ✓
17.6 EB05 16.4 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=603 · 100% clinicianno trial arm names this drug
Autism spectrum disorder2,01827.2
25.7–28.7ROR 27.3 · calibrated p 4e-4 ✓
17.4 EB05 16.8 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=2,017 · ♀ 31% (drug 65%) · 100% consumerno trial arm names this drug
Retinitis60526.4
23.9–29.2ROR 26.4 · calibrated p 5e-4 ✓
17.1 EB05 15.9 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=605 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Synovitis6,15024.0
23.3–24.7ROR 24.3 · calibrated p 8e-4 ✓
16.1 EB05 15.7 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious PRR 13.4 · ♀ 97% (drug 65%) · 90% clinicianno trial arm names this drug
C-reactive protein abnormal2,11322.8
21.7–24.1ROR 22.9 · calibrated p 0.001 ✓
15.5 EB05 15.0 · IC025 +3.9
3/3 methods agree
Lab value / disease markerserious n=2,108 · ♀ 100% (drug 65%) · 92% clinicianno trial arm names this drug
Pericarditis5,34621.9
21.2–22.6ROR 22.2 · calibrated p 0.001 ✓
15.1 EB05 14.8 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious PRR 12.1 · ♀ 98% (drug 65%) · 92% clinicianno trial arm names this drug
Sedation complication59314.4
13.1–15.8ROR 14.4 · calibrated p 0.008 ✓
11.1 EB05 10.4 · IC025 +3.3
3/3 methods agree
Reporting / coding artifactserious n=588 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Bursitis2,77513.8
13.2–14.4ROR 13.9 · calibrated p 0.009 ✓
10.8 EB05 10.5 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious PRR 10.0 · ♀ 96% (drug 65%)no trial arm names this drug
Blood pressure diastolic decreased1,70413.8
13.1–14.6ROR 13.9 · calibrated p 0.010 ✓
10.8 EB05 10.4 · IC025 +3.4
3/3 methods agree
Lab value / disease markerserious PRR 8.8no trial arm names this drug
Irritable bowel syndrome4,86013.6
13.2–14.1ROR 13.8 · calibrated p 0.010 ✓
10.7 EB05 10.5 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious PRR 10.6 · ♀ 97% (drug 65%)no trial arm names this drug
Temperature regulation disorder48613.2
12.0–14.6ROR 13.2 · calibrated p 0.012 ✓
10.4 EB05 9.7 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=478 · ♀ 100% (drug 65%)no trial arm names this drug
Bone erosion78713.2
12.2–14.3ROR 13.2 · calibrated p 0.012 ✓
10.4 EB05 9.8 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=786 · ♀ 100% (drug 65%) · 100% clinicianno trial arm names this drug
Hyperparathyroidism secondary54312.6
11.5–13.9ROR 12.6 · calibrated p 0.014 ✓
10.1 EB05 9.4 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=542no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Liver injury24,9654.24.1–4.2signal
Suicidality15,1313.03.0–3.1signal
Serious infection38,1422.42.4–2.4signal
Interstitial lung disease4,3482.22.1–2.3signal
Kidney injury20,4082.22.1–2.2signal
Hyponatraemia3,5012.12.0–2.2signal
Severe cutaneous reaction3,1752.12.0–2.1raised
Anaemia12,5652.02.0–2.1raised
Neutropenia / agranulocytosis10,2472.02.0–2.0raised
Fall / fracture15,6932.02.0–2.0raised
Gi bleeding7,3251.91.9–2.0raised
Anaphylaxis / angioedema4,7651.81.8–1.9raised
Thrombocytopenia8,2931.81.8–1.8raised
Opportunistic infection4,7551.71.6–1.7raised
Depression9,7291.71.6–1.7raised
Arrhythmia / qt6,4531.61.6–1.6raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Acetaminophen only as a background or rescue medication (NCT03472469, NCT04452344); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)37,6341.4
1.3–1.4ROR 1.4 · calibrated p 0.568
1.3 EB05 1.3 · IC025 +0.4Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.9no trial arm names this drug
Fatigue (tiredness)36,3472.3
2.2–2.3ROR 2.4 · calibrated p 0.867
2.2 EB05 2.2 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 2.6no trial arm names this drug
Off label use (used outside approved label)34,8571.9
1.9–2.0ROR 2.0 · calibrated p 0.949
1.9 EB05 1.9 · IC025 +0.9Reporting / coding artifactage-adj. PRR 1.7 · serious PRR 2.3no trial arm names this drug
Nausea31,4991.9
1.9–1.9ROR 2.0 · calibrated p 0.938
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 2.2no trial arm names this drug
Headache30,2412.3
2.3–2.4ROR 2.4 · calibrated p 0.839
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.2 · serious PRR 2.7no trial arm names this drug
Pain29,6102.3
2.3–2.4ROR 2.4 · calibrated p 0.845
2.3 EB05 2.2 · IC025 +1.2
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 2.6 · serious PRR 2.4no trial arm names this drug
Diarrhoea (diarrhea)25,0021.9
1.8–1.9ROR 1.9 · calibrated p 0.898
1.8 EB05 1.8 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 2.0no trial arm names this drug
Dyspnoea (shortness of breath)24,0552.0
2.0–2.1ROR 2.1 · calibrated p 0.998
2.0 EB05 2.0 · IC025 +1.0Labeled adverse reaction
exact term
age-adj. PRR 1.9 · serious PRR 2.0no trial arm names this drug
Arthralgia (joint pain)23,1472.7
2.7–2.8ROR 2.8 · calibrated p 0.686
2.6 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.4 · serious PRR 3.3no trial arm names this drug
Vomiting22,0372.3
2.2–2.3ROR 2.3 · calibrated p 0.883
2.2 EB05 2.2 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.2 · serious PRR 2.3no trial arm names this drug
Pyrexia (fever)20,4352.9
2.9–2.9ROR 3.0 · calibrated p 0.631
2.8 EB05 2.7 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.5 · serious PRR 2.5no trial arm names this drug
Rash18,4812.1
2.0–2.1ROR 2.1 · calibrated p 0.997
2.0 EB05 2.0 · IC025 +1.0Labeled — boxed warning
exact term
age-adj. PRR 2.0 · serious PRR 2.9no trial arm names this drug
Dizziness18,0281.7
1.7–1.8ROR 1.8 · calibrated p 0.808
1.7 EB05 1.7 · IC025 +0.7Not in label — unassessedage-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug
Asthenia (weakness)16,6382.1
2.1–2.2ROR 2.2 · calibrated p 0.962
2.1 EB05 2.1 · IC025 +1.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.9 · serious PRR 2.0no trial arm names this drug
Toxicity to various agents16,6355.1
5.0–5.2ROR 5.2 · calibrated p 0.210
4.7 EB05 4.6 · IC025 +2.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.4 · serious PRR 3.7 · 94% clinicianno trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Acetaminophen (paracetamol) ↔ Liver injury / hepatotoxicity.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Acetaminophen?

In FDA FAERS, the most frequently co-reported reaction terms for Acetaminophen are fatigue, nausea, headache, pain, diarrhoea, dyspnoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Acetaminophen have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.

Do FAERS signals prove that Acetaminophen causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.